Dr Chris Parker talks to ecancer managing editor Prof Gordon McVie at the European Multidisciplinary Cancer Conference in Stockholm about the pivotal ALSYMPCA, phase 3 trial.

The trial deals with radium 223, which is used to treat for bone metastasis in men with metastatic prostate cancer by emitting alpha particles that are highly damaging at only a short range. The trial hopes to show that the short range of radium 223 will destroy the cancer cells but not affect the bone marrow.